This inventor holds 1 USPTO granted patent. Top assignees: Innogenetics N.v., National Institute of Health and Medical Research, Sanofi. Active years: 2013.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 82 
1 out of 1,853 
1 out of 1,546 
Years Active: 2013
Title: Pierre Grognet: Innovator in Monoclonal Antibodies
Introduction
Pierre Grognet is a notable inventor based in Bruxelles Evere, Belgium. He has made significant contributions to the field of biotechnology, particularly in the development of diagnostic agents and drugs.
Latest Patents
Grognet holds a patent for "Antibodies specific of the β-amyloid peptides and their uses as diagnostic agents or drugs." This patent describes a monoclonal antibody that specifically binds to the N-terminal region of the Aβ peptide, with a high affinity for the peptide, facilitating immunological complex formation.
Career Highlights
Throughout his career, Grognet has worked with prominent organizations such as Innogenetics N.V. and the Institut National De La Santé Et De La Recherche Médicale. His work has been pivotal in advancing the understanding and treatment of diseases related to amyloid peptides.
Collaborations
Grognet has collaborated with esteemed colleagues, including Eugeen Vanmechelen and Nicolas Sergeant, contributing to various research initiatives and projects.
Conclusion
Pierre Grognet's innovative work in monoclonal antibodies has made a lasting impact on the field of biotechnology. His contributions continue to influence research and development in diagnostic and therapeutic applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile